Clinical Trials Logo
  1. Home
  2. Cat Allergy
  3. NCT02399579

Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients

Cat Allergy Clinical Trial

Official title:
Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients

Clinical Trial Summary

The purpose of this study is to better standardize the symptom recording of cat allergic persons under real-life conditions. A new self-assessed, home-based symptom score will be tested.

Clinical Trial Description

In order to bring research on cat dander allergy a step further we aim to investigate cat dander allergy symptoms and record them in a natural environment, respectively, i.e. at the participant's home. For this purpose we aim to test a new self-assessed, homebased symptom score (called HypoScore). The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The participants have to pet the cat everytime in the same manner. Directly before and after the provocation test the symptoms will be recorded in the eCRF by using an iPad mini. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02399579
Study type Interventional
Source University of Zurich
Contact
Status Completed
Phase N/A
Start date March 2015
Completion date June 2015
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02959073 - Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients N/A
Completed NCT00987909 - Exposure Chamber Trial With Cat Immunotherapy Phase 2
Completed NCT01383603 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis Phase 1
Completed NCT01383590 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis Phase 1
Completed NCT01003301 - The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge Phase 2
Completed NCT02311413 - A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy Phase 2
Completed NCT02237196 - Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy Phase 1/Phase 2
Terminated NCT01292070 - Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy Phase 0
Completed NCT00867906 - Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma Phase 2
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01033344 - Cat-PAD Exposure Chamber Study Phase 2
Completed NCT00685711 - Safety of Cat-PAD in Cat Allergic Subjects Phase 1/Phase 2
Completed NCT02040844 - Phase III Cat-PAD Follow-on Study Phase 3
Completed NCT01604018 - An Optional Two Year Follow Up Study to Study CP005A N/A
Completed NCT01272323 - Cat-PAD Follow on Study N/A
Completed NCT03838731 - Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge Phase 2
Completed NCT00729508 - Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects Phase 2
Recruiting NCT05331170 - Viral Mucosal Reprogramming Phase 2